Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma.

IF 1.6 Q4 ONCOLOGY

International Journal of Surgical Oncology Pub Date : 2021-09-13 eCollection Date: 2021-01-01 DOI:10.1155/2021/3946875

Manuel Díez-Alonso, Fernando Mendoza-Moreno, Remedios Gómez-Sanz, Belén Matías-García, Enrique Ovejero-Merino, Raquel Molina, Sonia Soto-Schütte, Alberto San Juan, Alberto Gutierrez-Calvo

{"title":"Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma.","authors":"Manuel Díez-Alonso, Fernando Mendoza-Moreno, Remedios Gómez-Sanz, Belén Matías-García, Enrique Ovejero-Merino, Raquel Molina, Sonia Soto-Schütte, Alberto San Juan, Alberto Gutierrez-Calvo","doi":"10.1155/2021/3946875","DOIUrl":null,"url":null,"abstract":"Objective: The main objective of the study was to determine the effect of the presence of mutation in the KRAS gene on the survival in patients with colorectal cancer (CRC) and peritoneal metastases (PM).Materials and methods: A retrospective cohort study was performed. Patients diagnosed with CRC with synchronous or metachronous PM between January 2006 and December 2019 were included. Data on the histopathological, clinical, and treatment factors were collected. The effect of each variable on survival was evaluated by Cox regression.Results: A total of 149 patients were included (64 women (43%) and 85 men (57%); mean age, 63 years). The long-term survival rate at 36 months was 24% (median, 21 months). KRAS mutation was detected in 75 patients (50.3%). Kaplan-Meier analysis estimated that likelihood of survival was higher in patients with wild-type KRAS tumours (35%) than in mutated-type KRAS (14%) (median: 28 vs. 15, respectively) (P=0.001). Within the categories into which the peritoneal cancer index (PCI) was classified, survival at 36 months depended on the KRAS status. Survival in wild-type KRAS tumours with PCI 1-10 was 71% and with PCI 11-20 was 26%, while in mutant-type KRAS tumours, survival was 41% and 4%, respectively (P=0.025). In the multiple regression analysis, the KRAS mutation was revealed to have an independent prognostic value (HR: 2.144; 95% CI: 1.342-3.424).Conclusion: The mutational status of the KRAS gene has demonstrated a strong association with survival and prognostic utility in patients with CRC with PM.","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455216/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/3946875","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Objective: The main objective of the study was to determine the effect of the presence of mutation in the KRAS gene on the survival in patients with colorectal cancer (CRC) and peritoneal metastases (PM).

Materials and methods: A retrospective cohort study was performed. Patients diagnosed with CRC with synchronous or metachronous PM between January 2006 and December 2019 were included. Data on the histopathological, clinical, and treatment factors were collected. The effect of each variable on survival was evaluated by Cox regression.

Results: A total of 149 patients were included (64 women (43%) and 85 men (57%); mean age, 63 years). The long-term survival rate at 36 months was 24% (median, 21 months). KRAS mutation was detected in 75 patients (50.3%). Kaplan-Meier analysis estimated that likelihood of survival was higher in patients with wild-type KRAS tumours (35%) than in mutated-type KRAS (14%) (median: 28 vs. 15, respectively) (P=0.001). Within the categories into which the peritoneal cancer index (PCI) was classified, survival at 36 months depended on the KRAS status. Survival in wild-type KRAS tumours with PCI 1-10 was 71% and with PCI 11-20 was 26%, while in mutant-type KRAS tumours, survival was 41% and 4%, respectively (P=0.025). In the multiple regression analysis, the KRAS mutation was revealed to have an independent prognostic value (HR: 2.144; 95% CI: 1.342-3.424).

Conclusion: The mutational status of the KRAS gene has demonstrated a strong association with survival and prognostic utility in patients with CRC with PM.

Abstract Image

查看原文本刊更多论文

KRAS基因突变对结直肠癌腹膜转移患者生存的预后价值。

目的:本研究的主要目的是确定KRAS基因突变对结直肠癌(CRC)和腹膜转移(PM)患者生存的影响。材料和方法:进行回顾性队列研究。研究纳入了2006年1月至2019年12月期间诊断为伴有同步或异时性PM的结直肠癌患者。收集组织病理学、临床和治疗因素的数据。采用Cox回归评价各变量对生存率的影响。结果:共纳入149例患者，其中女性64例(43%)，男性85例(57%);平均年龄63岁)。36个月的长期生存率为24%(中位21个月)。KRAS突变75例(50.3%)。Kaplan-Meier分析估计，野生型KRAS患者的生存可能性(35%)高于突变型KRAS患者(14%)(中位数分别为28 vs 15) (P=0.001)。在腹膜癌指数(PCI)的分类中，36个月的生存率取决于KRAS状态。PCI 1-10野生型KRAS肿瘤的生存率为71%，PCI 11-20野生型KRAS肿瘤的生存率为26%，而突变型KRAS肿瘤的生存率分别为41%和4% (P=0.025)。在多元回归分析中，KRAS突变具有独立的预后价值(HR: 2.144;95% ci: 1.342-3.424)。结论:KRAS基因的突变状态与结直肠癌合并PM患者的生存和预后密切相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Surgical Oncology ONCOLOGY-

CiteScore

3.70

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： International Journal of Surgical Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of surgical oncology.